Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Edwards Lifesciences

Is Edwards Lifesciences Stock Underperforming the Nasdaq?

Despite trailing the broader Nasdaq Composite over the last 12 months, Edwards Lifesciences continues to earn strong support from analysts.

Barchart

Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors

Healthcare stocks rebounded in 2025. These three healthcare growth stocks offer exposure to innovation beyond traditional biotech risk

MarketBeat

How Is Edwards Lifesciences’ Stock Performance Compared to Other Medical Device Stocks?

Edwards Lifesciences has notably outperformed the broader market over the past year, and analysts remain bullish on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Edwards Lifesciences Stock: Is Wall Street Bullish or Bearish?

Although Edwards Lifesciences has outpaced the broader market over the past year, analysts remain measured in their expectations, maintaining a cautiously optimistic view as they look for continued execution and sustained growth drivers.

Barchart

Here's What to Expect From Edwards Lifesciences’ Next Earnings Report

Edwards Lifesciences is all set to release its fiscal third-quarter earnings later this month, and analysts project a double-digit earnings drop.

Barchart

Edwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector?

As Edwards Lifesciences outshines the broader healthcare sector, Wall Street remains optimistic about its prospects.

Barchart

Edwards Lifesciences Stock: Analyst Estimates & Ratings

Though Edwards Lifesciences has outperformed the SPX over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

FTC Sounds Alarm On Edwards' Attempt To Corner Heart Device Market

The Federal Trade Commission (FTC) on Wednesday moved to block medical device supplier Edwards Lifesciences Corp.'s (NYSE:EW) proposed acquisition of JenaValve Technology, Inc.

Benzinga

Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance

Edwards Lifesciences’ (NYSE:EW) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.

Benzinga

Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results

Edwards Lifesciences Corporation (NYSE:EW) reported better-than-expected second-quarter financial results on Thursday.

Benzinga

Is Edwards Lifesciences Stock Underperforming the Dow?

Despite Edwards Lifesciences’ underperformance relative to the broader Dow over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Edwards Lifesciences Stock?

Despite Edwards Lifesciences’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

Is Edwards Lifesciences Stock Underperforming the S&P 500?

Edwards Lifesciences has recently underperformed the broader S&P 500, yet analysts remain moderately optimistic about the stock's potential.

Barchart

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

Analysts' ratings for Edwards Lifesciences (NYSE:EW) over the last quarter vary from bullish to bearish, as provided by 17 analysts.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

How Is Edwards Lifesciences' Stock Performance Compared to Other Medical Devices Stocks?

While Edwards Lifesciences has underperformed the broader medical devices industry recently, analysts are moderately bullish on the stock's prospects.

Barchart

Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?

Despite Edwards Lifesciences’ underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

What You Need to Know Ahead of Edwards Lifesciences' Earnings Release

Edwards Lifesciences is expected to release its second-quarter earnings this month, and analysts expect a single-digit profit increase.

Barchart

Edwards Lifesciences Stock: Is EW Underperforming the Healthcare Sector?

Edwards Lifesciences has recently underperformed the Healthcare sector, but Wall Street analysts anticipate a modest upside for the stock.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Medical device companies pay millions to NHS while pushing products, says study

Pharmaceutical equipment firms are funding NHS staff and training while promoting sales

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022

Upgrades

Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Edwards Lifesciences Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on Edwards Lifesciences (NYSE:EW). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Analyzing Edwards Lifesciences's Short Interest

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 166.36% since its last report. The company recently reported that it has 5.87 million shares sold short, which is 2.85% of all regular shares that are available for trading.

Benzinga

Peering Into Edwards Lifesciences's Recent Short Interest

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 6.33% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 0.84% of all regular shares that are available for trading.

Benzinga

Here's How Much $1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 16.51% on an annualized basis producing an average annual return of 22.72%. Currently, Edwards Lifesciences has a market capitalization of $55.48 billion.

1 2

People

Jonathan Evans

25 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.